Company: Dr. Reddy's Laboratories Ltd. Category: Company News

Under the agreement Dr. Reddy's sold its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg, which were commercialized through its wholly-owned subsidiary, Promius Pharma, LLC.
July 22, 2019, 11:01 a.m.

Under the agreement, Dr Reddy's sold its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg
July 20, 2019, 5:15 p.m.

Allegra-D 12 HR is a trademark of Aventisub II Inc
July 19, 2019, 11:55 a.m.

Reddy's OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20 and 30 count sizes.
July 19, 2019, 11:30 a.m.

Dr. Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.
June 25, 2019, 2:27 p.m.

Dr Reddy's Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules is available in 1 ml Ampule containing 10 mg/ml of Phytonadione
June 22, 2019, 7:25 p.m.

Pharma major Dr. Reddy’s Laboratories Ltd has launched Phytonadione Injectable Emulsion USP a therapeutic equivalent generic version of Vitamin K1 (P
June 22, 2019, 7 p.m.

As reduced commercialisation costs add to profitability, the growth in India and emerging markets is also encouraging
June 19, 2019, 4:47 p.m.

The detailed safety and efficacy data from the study would be presented in future dermatology conferences
June 10, 2019, 2:15 p.m.

The company has received the Establishment Inspection Report (EIR) from USFDA, for the facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated.
May 31, 2019, 9:26 a.m.